The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities The Global Blood Disorders Market is Forecast to Show Moderate Growth Due to a Series of Patent Expiries In 2009, the global blood disorders market was estimated to be worth $38.4 billion, representing a cumulative annual growth rate (CAGR) of 7.7% between 2001 and 2009. By 2016, the global blood disorders market is expected to reach $50.8 billion, indicating a CAGR of 4.1% between 2009 and 2016. The major reason behind the decline in the growth rate is the decline in the annual cost of treating blood disorders after 2011. The global blood disorders market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs in the anemia, thrombosis, hemophilia and neutropenia market. The major drugs that are set to lose patent protection between 2009 and 2016 are NovoSeven (2010), Plavix (2011), Lovenox (2012), Neupogen (2013), Epogen (2013), Procrit (2013), Kogenate (2014), Aranesp (2014) and Neulasta (2015). All of these drugs together account for more than $24 billion of revenues in the global blood disorders market. While the current blood disorders pipeline does offer some promising novel products, the revenues generated from these products are not expected to completely offset the revenue losses due to the patent expiries. Thus, in future, the overall market growth of the global blood disorders market is expected to decline. For more information, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=The-Future-of-Blood-DisordersTherapeutics-Analysis-and-Market-Forecasts-to-2016-Better-and-More-Cost-EffectiveTreatment-Options-CreateOpportunities&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals _and_Healthcare The Global Blood Disorders Market is Concentrated with the Top Five Companies Controlling Approximately 77% of the Market The current global blood disorders market is significantly consolidated as the top five players in the market control approximately 77% of the market. Amgen is the current market leader with four of its blockbuster products, Neulasta, Aranesp, Epogen and Neupogen, controlling 28% of the total blood disorders market. Sanofi-Aventis follows with a 22% market share, primarily due to its top selling anticoagulant Plavix, comarketed with BMS (Bristol-Myers Squibb), and its venous thrombosis drug Lovenox. BMS’ third position is attributed to the sales of Plavix, besides which, it does not have any significant presence in the branded blood disorders market. Ortho Biotech and Baxter are the forth and the fifth largest players, primarily due to Procrit, indicated for
anemia, and Advate, indicated for hemophilia, respectively. The companies control 7% and 5% of the total blood disorders market, respectively. However, the market shares of the top players are expected to witness changes in the future as two of the top companies in the current market, Amgen and Ortho Biotech, have been registering negative growth in recent years. On the other hand, the other three top companies, Sanofi-Aventis, BMS and Baxter, have shown a positive growth, more than the overall market growth. With M&A activity in the blood disorders market at a very low level, the future dominant players are expected to be those who come up with novel, safer, more efficacious and more convenient therapeutics in the blood disorders market. For more information, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=The-Future-of-Blood-DisordersTherapeutics-Analysis-and-Market-Forecasts-to-2016-Better-and-More-Cost-EffectiveTreatment-Options-CreateOpportunities&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals _and_Healthcare Large Number of Early Stage Licensing Deals in the Global Blood Disorders Market Reflects an Optimistic R&D Future The licensing landscape in the global blood disorders market has remained dry in absolute terms. During 2009 and the first two months of 2010, only 13 major licensing deals were signed. However, the positive aspect of these deals is that 69% of them involve early stage discovery molecules, which include the discovery, preclinical and Phase II stages. While 38% of the deals were signed for molecules in Phase II, 31% of the deals took place for the molecules in the preclinical and discovery Phase. Approximately 8% of the deals were signed for molecules in Phase III development. The approved drugs contributed to approximately 15% of the total licensing deals for the blood disorders market while 8% of the deals happened for drugs currently waiting for market approval. With a large majority of the deals involved in the early stage development drugs, it suggests that the market players are showing strong interest in strengthening the future pipeline potential of the industry. With a series of patent expiries expected to hit the blood disorders market, the need for novel drug candidates to successfully complete the clinical development stages and reach the market is strong. GBI Research, the leading business intelligence provider, has released its latest research, “The Future of Blood Disorders - Market Forecasts to 2016, Competitive Benchmarking, Product Pipeline and Deals Analysis�. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the
leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. For more information, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=The-Future-of-Blood-DisordersTherapeutics-Analysis-and-Market-Forecasts-to-2016-Better-and-More-Cost-EffectiveTreatment-Options-CreateOpportunities&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals _and_Healthcare Or Visit: http://www.gbiresearch.com
Contact Information: Rajesh Gunnam rgunnam@gbiresearch.com +914066166782